Verrica Pharmaceuticals Inc (VRCA) — Cash Flow-to-Debt Ratio
Verrica Pharmaceuticals Inc (VRCA) has a Cash Flow-to-Debt Ratio of -0.29x as of June 2026, meaning its operating cash flow of $-9.28 Million could theoretically repay 0% of its total liabilities ($31.71 Million) in one year. See Verrica Pharmaceuticals Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Verrica Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Verrica Pharmaceuticals Inc across 10 annual periods. For the full cash flow conversion analysis, see VRCA cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Verrica Pharmaceuticals Inc (2016–2025)
Year-by-year debt coverage analysis for Verrica Pharmaceuticals Inc. Check Verrica Pharmaceuticals Inc (VRCA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.79x | $-17.63 Million | $22.39 Million | ▲ +17.3% |
| 2024 | -0.95x | $-60.93 Million | $63.99 Million | ▼ -52.6% |
| 2023 | -0.62x | $-38.58 Million | $61.83 Million | ▲ +84.3% |
| 2022 | -3.98x | $-18.65 Million | $4.69 Million | ▼ -585.4% |
| 2021 | -0.58x | $-27.58 Million | $47.52 Million | ▲ +20.9% |
| 2020 | -0.73x | $-30.21 Million | $41.17 Million | ▲ +90.9% |
| 2019 | -8.04x | $-27.41 Million | $3.41 Million | ▼ -11.4% |
| 2018 | -7.22x | $-17.87 Million | $2.48 Million | ▼ -2438.7% |
| 2017 | -0.28x | $-4.58 Million | $16.12 Million | ▲ +43.4% |
| 2016 | -0.50x | $-1.61 Million | $3.21 Million | — |